Efficacy of biologic therapy on airway hyperresponsiveness in asthma

Rory Chan; Brian Lipworth

doi:10.1016/j.anai.2023.02.016

Efficacy of biologic therapy on airway hyperresponsiveness in asthma

Rory Chan, Brian Lipworth (Lead / Corresponding author)

Research output: Contribution to journal › Review article › peer-review

15 Citations (Scopus)

195 Downloads (Pure)

Abstract

Airway hyperresponsiveness refers to an exaggerated bronchial constrictor response to a given exogenous inhaled agent and is governed by airway smooth muscle along with mucosal inflammation in asthma. In recent years, the advent of biologics and antialarmins has transformed severe asthma treatment in terms of reducing oral-corticosteroid–requiring exacerbations and improving disease control, asthma quality of life, and spirometry-measured lung function. In contrast, there have been comparatively fewer studies investigating the efficacy of biologics in airway hyperresponsiveness. In this focused review, we summarize the existing evidence base in this area regarding omalizumab, mepolizumab, benralizumab, and tezepelumab.

Original language	English
Pages (from-to)	37-41
Number of pages	5
Journal	Annals of Allergy, Asthma and Immunology
Volume	131
Issue number	1
Early online date	22 Feb 2023
DOIs	https://doi.org/10.1016/j.anai.2023.02.016
Publication status	Published - Jul 2023

Keywords

omalizumab
mepolizumab
dupilumab
airway hyperresponsiveness
tralokinumab
benralizumab
tezepelumab

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Immunology and Allergy
Immunology

Access to Document

10.1016/j.anai.2023.02.016Licence: CC BY-NC-ND

Final published versionFinal published version, 748 KBLicence: CC BY-NC-ND

Cite this

@article{75316b27b0aa4f88ae5b8a2b0faa7d7c,

title = "Efficacy of biologic therapy on airway hyperresponsiveness in asthma",

abstract = "Airway hyperresponsiveness refers to an exaggerated bronchial constrictor response to a given exogenous inhaled agent and is governed by airway smooth muscle along with mucosal inflammation in asthma. In recent years, the advent of biologics and antialarmins has transformed severe asthma treatment in terms of reducing oral-corticosteroid–requiring exacerbations and improving disease control, asthma quality of life, and spirometry-measured lung function. In contrast, there have been comparatively fewer studies investigating the efficacy of biologics in airway hyperresponsiveness. In this focused review, we summarize the existing evidence base in this area regarding omalizumab, mepolizumab, benralizumab, and tezepelumab.",

keywords = "omalizumab, mepolizumab, dupilumab, airway hyperresponsiveness, tralokinumab, benralizumab, tezepelumab",

author = "Rory Chan and Brian Lipworth",

note = "Copyright: {\textcopyright} 2023 American College of Allergy, Asthma \& Immunology. Published by Elsevier Inc.",

year = "2023",

month = jul,

doi = "10.1016/j.anai.2023.02.016",

language = "English",

volume = "131",

pages = "37--41",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "American College of Allergy, Asthma and Immunology",

number = "1",

}

TY - JOUR

T1 - Efficacy of biologic therapy on airway hyperresponsiveness in asthma

AU - Chan, Rory

AU - Lipworth, Brian

PY - 2023/7

Y1 - 2023/7

N2 - Airway hyperresponsiveness refers to an exaggerated bronchial constrictor response to a given exogenous inhaled agent and is governed by airway smooth muscle along with mucosal inflammation in asthma. In recent years, the advent of biologics and antialarmins has transformed severe asthma treatment in terms of reducing oral-corticosteroid–requiring exacerbations and improving disease control, asthma quality of life, and spirometry-measured lung function. In contrast, there have been comparatively fewer studies investigating the efficacy of biologics in airway hyperresponsiveness. In this focused review, we summarize the existing evidence base in this area regarding omalizumab, mepolizumab, benralizumab, and tezepelumab.

AB - Airway hyperresponsiveness refers to an exaggerated bronchial constrictor response to a given exogenous inhaled agent and is governed by airway smooth muscle along with mucosal inflammation in asthma. In recent years, the advent of biologics and antialarmins has transformed severe asthma treatment in terms of reducing oral-corticosteroid–requiring exacerbations and improving disease control, asthma quality of life, and spirometry-measured lung function. In contrast, there have been comparatively fewer studies investigating the efficacy of biologics in airway hyperresponsiveness. In this focused review, we summarize the existing evidence base in this area regarding omalizumab, mepolizumab, benralizumab, and tezepelumab.

KW - omalizumab

KW - mepolizumab

KW - dupilumab

KW - airway hyperresponsiveness

KW - tralokinumab

KW - benralizumab

KW - tezepelumab

UR - https://www.scopus.com/pages/publications/85149835418

U2 - 10.1016/j.anai.2023.02.016

DO - 10.1016/j.anai.2023.02.016

M3 - Review article

C2 - 36841374

SN - 1081-1206

VL - 131

SP - 37

EP - 41

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

IS - 1

ER -

Efficacy of biologic therapy on airway hyperresponsiveness in asthma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this